Cardiovascular disease remains a leading global health burden, yet many preclinical systems still struggle to predict how candidate drugs will perform in the human heart.
LONDON--(BUSINESS WIRE)--The prevalence of cardiac arrhythmias has increased significantly in recent years, owing to the increased risk of stroke and hospitalizations. This is encouraging various ...